sing data from the Norwegian Arthroplasty Register, we have assessed the survival of 17 323 primary Charnley hip prostheses in patients with osteoarthritis based upon the type of cement used for the fixation of the implant.
In patients with severe arthritis total hip replacement (THR) usually provides relief from pain and improved physical function. 1, 2 The clinical benefit has been shown to last for decades 3, 4 and is cost-effective in improving quality-adjusted life years. 5 There are an estimated one million THRs performed worldwide each year, 6 but, because of this high number even low rates of failure involve large numbers of patients. The longevity of the second prosthesis 7 and patient satisfaction and function 8 are reduced when compared with those of primary surgery. Our knowledge of the clinical effectiveness and safety of implanted medical devices is much less than that for drugs. A major reason is that marketing regulations, both in the USA and Western Europe, have been less strict than for drugs. 9, 10 For example, examination of the effect of treatment in randomised trials is not required before marketing. Poor results have been reported for some hip implants in several large, prospective studies. [11] [12] [13] [14] The effect of the type of cement has been considered in only a few reviews, which showed poor results for Boneloc and for the lowviscosity cements CMW3 15, 16 and Sulfix, 13 compared with high-viscosity cement.
We have assessed the survival at ten years of 17 323 primary Charnley THRs reported to the Norwegian Arthroplasty Register, which were fixed with either one of three high-viscosity cements, Palacos, Simplex and CMW1, or the low-viscosity type CMW3.
Patients and Methods
The Norwegian Arthroplasty Register was established in September 1987. 17 Individual reports of THRs have since been received from all the 69 hospitals in Norway which carried out this procedure and at least 95% of all THRs performed are reported to the register. 14 Information including the date of operation, the identity of the patient, the indication for the procedure, the type of prosthesis and the type of cement is reported on a standardised form by the surgeon. Failure of the implant is defined as the surgical removal or exchange of the whole or part of the implant. Linkage of information on the primary and subsequent operations is possible by use of the unique identification number assigned to each resident of Norway. As of 1 May 2000, data had been collected on 61 467 primary THRs, of which 3534 had failed. Study sample. Our study group comprised THRs performed between 15 September 1987 and 1 May 2000. In order to investigate the effect of the type of cement, unconfounded by the design of the prosthesis, only Charnley implants (DePuy, Leeds, UK) were included in the study (n = 28 127). These were selected since they constituted 46% of the prostheses used in primary operations and had been used with several types of cement. The clinical performance of the Charnley prosthesis is well documented for more than 20 years. 3, 4 Only patients operated on for primary osteoarthritis (73%) and with no previous operation on the hip (83%) were included. This reduced the number to 20 176 operations. If there was no information on survival time, or on one or more of the covariates included in the analyses, the case was excluded (n = 678). We also required that the same type of cement had been used for both acetabular and femoral fixation. For the remaining operations (n = 18 164), only those performed with the most commonly used types of cement were included (n = 17 323). These were the high-viscosity cements Palacos with (n = 9186) and without (n = 2115) gentamicin (0. was also considered. Information on the particular design of the cup or stem was unavailable in 4.1% of the operations and the covariate was included in the model both with and without a specific level for missing information. However, adjustment for the design of the prosthesis had only a negligible influence on the results.
In the Cox models, the covariates age and operating time were represented with indicator variables since the assumption of a log-linear relationship between these factors and the failure rate was untenable. Failure RRs are presented with 95% confidence intervals relative to the reference category. The average covariance was supplied to facilitate the computation of confidence intervals for alternative choices of reference category. 19 Unadjusted probabilities at ten-years or failure were estimated using the Kaplan-Meier method. 20 Estimates from Cox analyses, with the type of cement as the stratification factor, were used to construct survival curves at mean values of the covariates, and to compute ten-year adjusted probabilities of failure. Survival analyses were also performed separately for the acetabular and femoral components, with the endpoint being defined as failure of the prosthesis because of aseptic loosening of the respective component. Tests performed for the cement covariate indicated no violation of the proportional hazards assumption. 21 The statistical software programs SPSS version 9.0 (SPSS Inc, Chicago, Illinois) 22 and S-Plus 2000 (MathSoft Inc, Seattle, Washington) 23 were used for the statistical analyses.
Results
Baseline characteristics. High-viscosity types of cement were used in 97% of the operations. Table I shows the characteristics of the patient, hospital, and procedure by the type of cement. No cement was strongly associated with a particular gender or age group. Follow-up. The overall unadjusted ten-year risk of failure due to any cause was 9.2% (95% CI 8.5 to 9.9), and varied from 6.8% (95% CI 5.8 to 7.8) for implants cemented with gentamicin-containing Palacos cement to 17% (95% CI 13 to 21) for CMW3 cement without gentamicin. With failure due to aseptic loosening as the endpoint, the overall unadjusted ten-year probability of failure was 7.4% (95% CI 6.8 to 8.1). Table II and Figures 1 and 2 show that the lowest rates of failure were observed in implants fixed with either Palacos or Simplex cement. With gentamicin-containing Palacos cement as reference, the adjusted Cox regression failure RRs due to any cause were 1.1 (95% CI 0.9 to 1.4) for implants cemented with plain Palacos, 1.1 (95% CI 0.7 to 1.6) with Simplex, 2.1 (95% CI 1.5 to 2.9) with gentamicin-containing CMW1, 2.0 (95% CI 1.6 to 2.4) with plain CMW1 and 3.0 (95% CI 2.3 to 3.9) for implants fixed with CMW3 cement (Table II) . These findings were strengthened with failure due to aseptic loosening as the endpoint (Table II) . Most failures involved aseptic loosening of the femoral component (Table II, Fig. 2 ). Of 609 failures due to aseptic loosening, 28 were caused by loosening of the acetabular component only, 373 of the femoral component only, and 208 of both components. The risk of failure was similar for implants cemented with gentamicin-containing Palacos and with plain Palacos. This was also observed for gentamicin-containing CMW1 cement as against plain CMW1 with any failure as the endpoint (adjusted RR = 1.1, p = 0.77). However, with failure due to aseptic loosening as the endpoint, CMW1 with gentamicin had an increased, but not statistically significant, risk of failure compared with plain CMW1 (adjusted RR = 1.4, p = 0.08).
The use of Palacos and CMW1 with gentamicin increased during the period of study. While gentamicin- containing cement was used for 42% of prostheses inserted between 1987 and 1994, the proportion had increased to 83% between 1995 and 2000 (Fig. 3) . Restricting the material to operations performed between 1987 and 1994 gave results similar to those already described. Between 1995 and 2000 the differences were less pronounced.
With failures due to aseptic loosening as the endpoint, the adjusted failure rate of implants cemented with CMW1 with and without gentamicin was 2.5 (95% CI 1.6 to 4.0, p < 0.001) and 1.7 (95% CI 1.0 to 3.0, p = 0.05) times that of implants inserted with gentamicin-containing Palacos cement. Survival curves calculated for 17 323 Charnley THRs with type of cement as the strata factor and any failure of either component as the endpoint (817 failures). The Kaplan-Meier method was applied to construct unadjusted estimates (a) and the Cox proportional hazards method was used for adjusted estimates (b). There were significant differences in survival for the different types of cement used (p < 0.001). The unadjusted and adjusted survival results were similar. 
Discussion
Using data from the prospective Norwegian Arthroplasty Register between 1987 and 2000, we have shown important differences in failure rates for Charnley total hip prostheses when different types of cement are used for fixation. The low-viscosity cement, CMW3, and the high-viscosity cement, CMW1, showed an increased risk of long-term failure when compared with the high-viscosity cements Palacos and Simplex.
The principal finding of our study was the variation in rates of failure observed for the different types of cement. At ten years, we observed a probability of failure of 12% for prostheses fixed with plain CMW1 cement compared with 7% for those with plain Palacos cement. Furthermore, our study extends our previous observation of increased failure rates associated with low-viscosity CMW3 cement. 15 were revised after follow-up for only two years. 15 Boneloc cement is no longer produced, and use of the low-viscosity cements, Sulfix and CMW3, has been abandoned in Norway and Sweden. It has been suggested that cements which contain barium sulphate (BaSO 4 ) as a radio-opacifier are likely to be associated with more osteolysis than those which contain zirconium dioxide (ZrO 2 ). 27, 28 While laboratory testing has shown that the addition of an antibiotic to bone cement may compromise the mechanical strength of that cement, 32 data on the clinical relevance of this finding have been sparse. In Norway, the use of antibiotic-containing cement for the fixation of either component has increased from 40% in 1989 to 94% in 1999. We observed no significant difference in the failure rates for prostheses inserted with Palacos cement, with or without added gentamicin. The same was observed for prostheses cemented with CMW1, taking any failure as the endpoint. With failure due to aseptic loosening as the endpoint, however, worse results were indicated when gentamicin-impregnated CMW1 cement was used. It has been argued that weaker cements may be more adversely affected by the addition of an antibiotic. 32 Results from observational, register-based studies are often regarded as being less conclusive than those from comparable randomised trials. However, recent studies have indicated that properly conducted large prospective reviews may give results which are similar to those of randomised trials. 35, 36 In our study, we have controlled for confounding through regression analyses and by limiting the analyses to Charnley THRs in patients with primary coxarthrosis. Frequently, a strong association appears between the use of specific prostheses and cements because the same company markets both products. In Norway, only the Charnley prosthesis had been used with different types of cement in any great numbers. It has been shown that The distribution of types of cement used for fixation of Charnley THRs by year of operation.
Exeter femoral components cemented with Boneloc have a lower risk of failure than Charnley femoral components implanted with this cement. 16 This finding shows that the type of prosthesis may modify the effect of cement on failure rates and that our results based on the Charnley implant need to be compared with other designs of cemented prostheses. Potentially important risk factors such as the surgeon's personal cementing technique and cement mixing systems 37 were not reported to the Norwegian Arthroplasty
Register and are thus not considered in our study. However, so-called modern techniques of cementing [38] [39] [40] were commonly used during the period of review. Preliminary results from a study based on data in the Norwegian Arthroplasty Register and a survey among Norwegian hospitals into the use of vacuum mixing, showed that vacuum mixing was introduced in 1992 and was used by most hospitals by 1997. In our study, analyses restricted to different periods of time showed similar results among the brands of cement.
Previous studies have reported low rates of revision for many cemented implants currently in use. 13, 14, 41, 42 We have
shown that the choice of cement used for fixation has important consequences for the long-term durability of the implant and represents an argument for greater awareness regarding the current marketing regulations of medical devices.
